Performance evaluation of the MALDI Biotyper Selective Testing of Antibiotic Resistance–β-Lactamase (MBT STAR-BL) assay for the detection of IMP metallo-β-lactamase activity in Enterobacteriaceae

Kawamoto, Yasuhide; Kosai, Kosuke; Yamakawa, Hiromi; Kaku, Norihito; Uno, Naoki; Morinaga, Yoshitomo; Hasegawa, Hiroo; Miyazaki, Taiga; Izumikawa, Koichi; Mukae, Hiroshi; Yanagihara, Katsunori

doi:10.1016/j.diagmicrobio.2018.06.018

Cited by 9 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite these limitations, the successful application of the assay has been documented for a wide array of bacterial species [ Acinetobacter sp. (Kempf et al, 2012; Alvarez-Buylla et al, 2013; Carvalhaes et al, 2013); Bacteroides (Johansson et al, 2014b); Pseudomonas (Carvalhaes et al, 2013; Lee et al, 2013); and Enterobacteriaceae (Sparbier et al, 2012; Jung et al, 2014b; Oviaño et al, 2016a; Calderaro et al, 2017; Choquet et al, 2018]; with different antibiotics as substrate [ampicillin (Jung et al, 2014b); cefotaxime and ceftazidime (Oviaño et al, 2014, 2017a; Li et al, 2017); ertapenem (Burckhardt and Zimmermann, 2011; Carvalhaes et al, 2013; Hoyos-Mallecot et al, 2014; Johansson et al, 2014a); imipenem (Knox et al, 2014; Chong et al, 2015; Lasserre et al, 2015; Ghebremedhin et al, 2016); meropenem (Hrabák et al, 2011; Wang et al, 2013a; Kawamoto et al, 2018)]; with inoculae collected from positive blood-cultures (Carvalhaes et al, 2014; Johansson et al, 2014b; Jung et al, 2014b; Oviaño et al, 2014) or urine samples (Oviaño et al, 2017b) and with isolates possessing different lactamases.…”

Section: Monitoring Antibiotic Degradationmentioning

confidence: 99%

“…A software module to evaluate spectra acquired in degradation assay, MBT STAR ® -BL, has been developed and commercialized by Bruker Daltonik (Bremen, Germany), together with a sample preparation kit (MBT STAR ® -Carba IVD Kit). This software makes the manual and hence tedious identification of peaks related to native and degraded antibiotics obsolete and yields a result through semi-automated data processing and has been tested in several clinical studies (Papagiannitsis et al, 2015; Oviaño et al, 2017a; Kawamoto et al, 2018; Rapp et al, 2018).…”

Section: Monitoring Antibiotic Degradationmentioning

confidence: 99%

See 1 more Smart Citation

One System for All: Is Mass Spectrometry a Future Alternative for Conventional Antibiotic Susceptibility Testing?

Welker

Belkum

2019

Front. Microbiol.

View full text Add to dashboard Cite

The two main pillars of clinical microbiological diagnostics are the identification of potentially pathogenic microorganisms from patient samples and the testing for antibiotic susceptibility (AST) to allow efficient treatment with active antimicrobial agents. While routine microbial species identification is increasingly performed with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), routine AST still largely relies on conventional and molecular techniques such as broth microdilution or disk and gradient diffusion tests, PCR and automated variants thereof. However, shortly after the introduction of MALDI-TOF MS based routine identification, first attempts to perform AST on the same instruments were reported. Today, a number of different approaches to perform AST with MALDI-TOF MS and other MS techniques have been proposed, some restricted to particular microbial taxa and resistance mechanisms while others being more generic. Further, while some of the methods are in a stage of proof of principles, others are already commercialized. In this review we discuss the different principal approaches of mass spectrometry based AST and evaluate the advantages and disadvantages compared to conventional and molecular techniques. At present, the possibility that MS will soon become a routine tool for AST seems unlikely – still, the same was true for routine microbial identification a mere 15 years ago.

show abstract

Section: Monitoring Antibiotic Degradationmentioning

confidence: 99%

Section: Monitoring Antibiotic Degradationmentioning

confidence: 99%

One System for All: Is Mass Spectrometry a Future Alternative for Conventional Antibiotic Susceptibility Testing?

Welker

Belkum

2019

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…This has become a popular assay commonly used in clinical diagnostic laboratories; however, it does not provide any resistance information. Bruker have developed the MBT-STAR assay for the Biotyper instrument that can measure b-lactam resistance by detecting the hydrolysis products of b-lactam drugs (Kawamoto et al, 2018). While this is useful, it only applies to this specific drug class and resistance mechanism; therefore, it is not universally applicable.…”

Section: Introductionmentioning

confidence: 99%

Rapid detection of antimicrobial resistance in methicillin-resistant Staphylococcus aureus using MALDI-TOF mass spectrometry

Rensner,

Lueth,

Bellaire

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Antimicrobial resistance is a growing problem in modern healthcare. Most antimicrobial susceptibility tests (AST) require long culture times which delay diagnosis and effective treatment. Our group has previously reported a proof-of-concept demonstration of a rapid AST in Escherichia coli using deuterium labeling and MALDI mass spectrometry. Culturing bacteria in D2O containing media incorporates deuterium in newly synthesized lipids, resulting in a mass shift that can be easily detected by mass spectrometry. The extent of new growth is measured by the average mass of synthesized lipids that can be correlated with resistance in the presence of antimicrobials. In this work, we adapt this procedure to methicillin-resistant Staphylococcus aureus using the Bruker MALDI-TOF Biotyper, a low-cost instrument commonly available in diagnostic laboratories. The susceptible strain showed a significant decrease in average mass in on-target microdroplet cultures after 3 hours of incubation with 10 µg/mL methicillin, while the resistant strain showed consistent labeling regardless of methicillin concentration. This assay allows us to confidently detect methicillin resistance in S. aureus after only 3 hours of culture time and minimal sample processing, reducing the turn-around-time significantly over conventional assays. The success of this work suggests its potential as a rapid AST widely applicable in many clinical microbiology labs with minimal additional costs.

show abstract

“…Imipenem was chosen as an antibiotic, because it is the carbapenem molecule that enables the best balance between sensitivity and specificity. This method was evaluated in different studies and with heterogeneous datasets, [64][65][66][67][68][69] showing excellent performance, and EUCAST guidelines for confirmation of carbapenemase activity also recommend the carbapenem hydrolysis assay by MALDI-TOF MS among the suggested methods. 70 In this study, we evaluated the performance of MBT STAR-Carba assay retrospectively, with clinical and surveillance isolates from plate cultures, and prospectively, with positive blood cultures.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the MBT STAR-Carba Assay for the Detection of Carbapenemase Production in Enterobacteriaceae and Hafniaceae with a Large Collection of Routine Isolates from Plate Cultures and Patient-Derived Positive Blood Cultures

Cordovana

Abdalla

Ambretti

2020

Microbial Drug Resistance

View full text Add to dashboard Cite

The spread of carbapenemase-producing Enterobacterales is a major public health concern worldwide, and methods for their prompt and reliable detection are highly demanded for therapeutic and hygiene control purposes. In this study, we evaluate the MBT STAR Ò-Carba assay (Bruker Daltonik) to detect the carbapenemase production in clinical and surveillance isolates from plate cultures and directly from patient-derived positive blood cultures bottles. Overall, n = 1,307 samples were analyzed (n = 900 plate cultures, and n = 407 positive blood cultures, using the bacterial pellet obtained with the Sepsityper Ò Kit; Bruker Daltonik), including n = 793 carbapenemase producers (n = 579 Klebsiella pneumoniae carbapenemase, n = 161 metallo-beta-lactamases, n = 45 OXA-48, and eight isolates harboring two different enzymes), n = 239 carbapenem-resistant noncarbapenemase producers, and n = 275 carbapenem-susceptible strains. The STAR-Carba assay detected 657/661 (99.4%) carbapenemase producers from plate cultures, and 132/132 (100%) from positive blood cultures. Specificity resulted in 100% for carbapenem-susceptible strains, and 91.6% for carbapenem-resistant strains resulted negative for carbapenamase production with the routine methods used in this study. In this study, the MBT STAR-Carba assay proved to be a highly reliable method for the detection of carbapenemaseproducing Enterobacterales, regardless of the enzyme family, and from both plate cultures and positive blood culture bottles.

show abstract

Performance evaluation of the MALDI Biotyper Selective Testing of Antibiotic Resistance–β-Lactamase (MBT STAR-BL) assay for the detection of IMP metallo-β-lactamase activity in Enterobacteriaceae

Cited by 9 publications

References 16 publications

One System for All: Is Mass Spectrometry a Future Alternative for Conventional Antibiotic Susceptibility Testing?

One System for All: Is Mass Spectrometry a Future Alternative for Conventional Antibiotic Susceptibility Testing?

Rapid detection of antimicrobial resistance in methicillin-resistant Staphylococcus aureus using MALDI-TOF mass spectrometry

Evaluation of the MBT STAR-Carba Assay for the Detection of Carbapenemase Production in Enterobacteriaceae and Hafniaceae with a Large Collection of Routine Isolates from Plate Cultures and Patient-Derived Positive Blood Cultures

Contact Info

Product

Resources

About